ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

计划入组 148 人 · 首次发布于 2023 年 1 月 12 日

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

计划入组 1,524 人 · 首次发布于 2025 年 10 月 1 日

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

计划入组 20 人 · 首次发布于 2026 年 7 月 6 日

Lutetium Lu-177 vipivotide tetraxetan(Pluvicto)

C₄₉H₆₈LuN₉O₁₆

Zalsenertant tetraxetan lutetium Lu-177

Lutetium Lu-177(Lutathera, Lumark, EndolucinBeta, Lutetium (177Lu) chloride Billev (previously Illuzyce))

Lu

Laureate Institute for Brain Research

United States

Aveta Biomics, Inc.

United States

Selcuk University

Turkey

PSMA-Targeted Therapies Transform Prostate Cancer Treatment Landscape

Lutetium Lu 177 Vipivotide Tetraxetan Shows Promise in Prostate Cancer Treatment

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for PSMA-Positive Metastatic Castration-Resistant Prostate Cancer